Medical Amino Acid Market Report 2026

The medical amino acid market size has grown strongly in recent years. It will grow from $4.11 billion in 2025 to $4.44 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to limited awareness of amino acid therapies, reliance on conventional protein supplements, increasing hospital and clinic adoption, growth in nutraceutical research, restricted availability of specialty amino acids.

The medical amino acid market size is expected to see strong growth in the next few years. It will grow to $5.99 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to advancements in medical amino acid synthesis, rising demand for personalized nutrition, expansion of clinical and hospital applications, growing pharmaceutical and cell culture research, development of novel delivery methods for amino acids. Major trends in the forecast period include rising demand for amino acid-based medical nutrition, growth in specialized supplements for metabolic disorders, increased adoption of injectable amino acid formulations, expansion of amino acids in pharmaceutical intermediates, focus on high-purity and clinical-grade amino acid products.

The rising incidence of liver diseases is expected to drive growth in the medical amino acid market in the coming years. Liver disease encompasses a range of disorders that impair the liver’s structure or function, disrupting its vital roles in the body. The prevalence of liver diseases is increasing, largely due to rising obesity rates, which contribute to non-alcoholic fatty liver disease by causing fat accumulation in liver cells and impairing their function. Medical amino acids help manage liver-related metabolic imbalances and support liver cell regeneration, making them essential components of nutritional therapy for affected patients. For example, in September 2025, the Centers for Disease Control and Prevention (CDC), a U.S.-based federal public health agency, reported that chronic liver disease and cirrhosis caused 52,222 deaths in the United States in 2023, ranking as the ninth leading cause of death. This demonstrates that the increasing prevalence of liver diseases is fueling growth in the medical amino acid market.

Key companies in the medical amino acid market are focusing on developing innovative formulations, such as high-calorie parenteral nutrition injections, to improve patient nutrition and support recovery for those unable to consume food orally. High-calorie parenteral nutrition injections are nutrient-rich solutions delivered intravenously, containing amino acids, glucose, electrolytes, and vitamins, which help meet energy requirements, support protein synthesis, and aid recovery in patients with impaired oral intake or absorption. For example, in November 2024, Otsuka Pharmaceutical Factory Inc., a Japan-based pharmaceutical and nutrition company, launched KIDPAREN Injection, a kit formulation for high-calorie parenteral nutrition tailored to chronic kidney disease (CKD) patients. The product features a 1,050 mL three-chamber bag combining amino acids, glucose, electrolytes (excluding potassium and phosphorus), and multivitamins, providing approximately 1,500 kcal in a fluid-restricted volume. The kit allows easy aseptic mixing by breaking the center seal before infusion, simplifying administration compared to traditional parenteral nutrition, which requires separate preparation of amino acids, TPN bases, vitamins, and electrolytes, reducing preparation time, minimizing compounding errors, and easing the burden on healthcare providers.

In October 2023, Grand Pharmaceutical Group Limited, a Hong Kong-based pharmaceutical company, acquired Hubei Bafeng for $37.24 million (RMB 270 million). Through this acquisition, Grand Pharmaceutical Group aimed to expand production capacity and diversify its portfolio by integrating Hubei Bafeng’s expertise in amino acid active pharmaceutical ingredients (APIs) and clinical nutrition products. Hubei Bafeng is a China-based provider of medical amino acids.

Major companies operating in the medical amino acid market are Evonik Industries AG, Ajinomoto Co. Inc., Nippon Kayaku Co. Ltd., FUJIFILM Irvine Scientific, Kyowa Hakko Bio Co. Ltd., Aelicure Pharma, Shanghai Kyowa Amino Acid Co. Ltd.

North America was the largest region in the medical amino acid market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical amino acid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical amino acid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the medical amino acid market by increasing the cost of imported raw materials and specialty synthesis equipment. Segments such as injectable formulations and pharmaceutical intermediates are most impacted, with Asia-Pacific regions including China and India experiencing higher import duties. These tariffs have raised production costs and caused supply chain disruptions. However, they also encourage local manufacturing, investment in domestic production, and innovation in alternative synthesis methods, potentially strengthening regional capabilities.

The medical amino acid market research report is one of a series of new reports that provides medical amino acid market statistics, including medical amino acid industry global market size, regional shares, competitors with a medical amino acid market share, detailed medical amino acid market segments, market trends and opportunities, and any further data you may need to thrive in the medical amino acid industry. This medical amino acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical amino acids are specially formulated amino acids created to support specific physiological requirements, particularly in individuals with metabolic or health conditions that affect protein digestion or amino acid absorption. These amino acids are designed to provide precise nutritional content, ensuring a balanced supply of essential and non-essential amino acids needed for the body’s growth, repair, and maintenance.

The primary product types of medical amino acids include L-glutamine, L-arginine, L-lysine, L-leucine, L-isoleucine, L-valine, and others. L-glutamine is a conditionally essential amino acid, meaning the body generally produces sufficient amounts, but supplementation is required during illness, injury, or stress. These amino acids are used in medical supplements, medicinal foods, active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and cell culture ingredients, and are utilized by various end users, including hospitals, research laboratories, clinics, pharmaceutical companies, and nutraceutical firms.

The medical amino acid market consists of sales of amino acid blends, protein-free medical formulas, amino acid powders, and amino acid-based drinks. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.